Form 4: Heron Therapeutics CFO Acquires Shares via RSU Vesting

Heron Therapeutics' EVP and CFO, Ira Duarte, acquired 3,874 shares of common stock through the scheduled vesting of restricted stock units on October 19, 2025.

Summary

• Ira Duarte, Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. (HRTX), acquired 3,874 shares of common stock.
• The acquisition occurred on October 19, 2025, as a result of the vesting of restricted stock units (RSUs).
• Following this transaction, Duarte directly beneficially owns 168,092 shares of common stock.
• Duarte also holds 34,869 restricted stock units.
• The restricted stock units vest in 16 equal quarterly installments, with the vesting schedule commencing one quarter after the grant date of January 19, 2024.

Sentiment

Score: 6

Explanation: The acquisition of shares by the CFO through RSU vesting is a routine compensation event, increasing insider ownership without indicating a discretionary purchase or sale, thus having a mildly positive but not significant impact.

Positives

• EVP and CFO Ira Duarte increased direct beneficial ownership of common stock, which can be viewed as a positive signal of alignment with shareholder interests, even if routine.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This is a routine insider transaction related to executive compensation, which is a common practice across publicly traded companies in various industries. It does not inherently reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The increase in insider ownership, even through routine vesting, may be viewed as a positive alignment of management's interests with those of shareholders.

Next Steps

• Remaining restricted stock units held by Ira Duarte will continue to vest in subsequent quarterly installments according to the established schedule.

Key Dates

Recommendation

The filing details a routine insider transaction involving the vesting of restricted stock units for the EVP and CFO. While it increases insider ownership, it does not represent a discretionary purchase or sale that would significantly alter the investment thesis for Heron Therapeutics. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide new material information to change an existing position.

Keywords

Heron Therapeutics, HRTX, Ira Duarte, CFO, Insider Transaction, Form 4, Restricted Stock Units, Stock Acquisition, Executive Compensation